The close chemical relationship between glyceryl trinitrate and erythrol tetranitrate suggests that these 2 drugs, despite clinical evidence to the contrary, should be equally effective in preventing attacks of angina pectoris. This proved to be true when the drugs were administered by the same route. Thus, erythrol tetranitrate when administered sublingually (instead of being swallowed, as is the custom) behaves like nitroglycerin and is one of the most effective vasodilators available. Conversely, nitroglycerin when swallowed (instead of being taken sublingually, as is the custom) is ineffective and erratic in activity. A similar striking increase in vasodilating action on sublingual administration is seen also with mannitol hexanitrate and triethanolamine trinitrate and to a lesser extent with pentaerythritol tetranitrate but not with sodium nitrite.
The close chemical relationship between glyceryl trinitrate and erythrol tetranitrate suggests that these 2 drugs, despite clinical evidence to the contrary, should be equally effective in preventing attacks of angina pectoris. This proved to be true when the drugs were administered by the same route. Thus, erythrol tetranitrate when administered sublingually (instead of being swallowed, as is the custom) behaves like nitroglycerin and is one of the most effective vasodilators available. Conversely, nitroglycerin when swallowed (instead of being taken sublingually, as is the custom) is ineffective and erratic in activity. A similar striking increase in vasodilating action on sublingual administration is seen also with mannitol hexanitrate and triethanolamine trinitrate and to a lesser extent with pentaerythritol tetranitrate but not with sodium nitrite.
The prolonged effect of erythrol tetranitrate, when administered sublingually or in the buccal pouch, makes it particularly valuable in the clinical management of patients with angina pectoris.
OF ALL the drugs available for preventing attacks of angina pectoris nitroglycerin, amyl nitrite, and octyl nitrite are by far the most effective. Of these 3, nitroglycerin is the most widely used, primarily because of its definite dosage, simplicity of administration, and low cost. The one drawback to its clinical usefulness is the short duration of action. Measurements in this laboratory' demonstrated that, although the prophylactic benefit of sublingual nitroglycerin may persist for an hour in some patients, its action persists for minutes only in most patients. Similar studies with other drugs' 6 showed that nitroglycerin is of prophylactic benefit to more patients and to a greater degree than any other medication. The present report is concerned with a search for drugs as effective as nitroglycerin, but with more prolonged activity.
The graphic chemical formulas of the 6 Presented in part before the New England Cardiovascular Society, February 8, 1954. 22 nitrites studied in the present series are shown in figure 1 . If the action of nitroglycerin is due to the presence of -ONO2 groups, all 6 should have therapeutic value in angina pectoris.
Two problems were of particular interest. First, since the chemical structures of nitroglycerin and erythrol tetranitrate are similar, why is the former much more effective for preventing attacks of angina pectoris? Second, since laboratory studies show that sodium nitrite has a highly effective vasodilating action, why is this drug of such limited clinical value in treating angina pectoris? A study of the extensive literature suggests that part of the difference in clinical effectiveness of these 6 drugs may be due to the various routes of administration employed.
Nitroglycerin or glycerol trinitrate is an oily liquid and, originally, was used in alcoholic solution, i.e., tincture glanoin. The vivid description by Field in 18587 showed that this solution, when dropped on the tongue, was readily absorbed by the mucous membranes of the mouth with striking effects. One of the patients treated by Field may well have suffered from angina pectoris, but Nitroglycerin is readily absorbed from thl skin.'2' 13 An ointment containing nitroglycerin has recently been made available conimercially for the treatment of peripheral vaseular disease. This preparation has been us-ed with some clinical success in some patients with angina pectoris.'4 '1 Erythrol tetranitrate, according to the graphic formula, should be an ideal drug because it is identical with glycerol trinitrate except that its molecule is 1/.3 larger; this might well prolong its activity without de- tracting from its effectiveness. Bradbury 's early studies'6 and also subsequent measurements '7-19 showed that both drugs are effective in lowering the blood pressure of laboratory animals but erythrol tetranitrate has a more prolonged action. However, exercise tolerance and electrocardiographic measurements4' 6, 20 showed that although erythrol tetranitrate is of some prophylactic value in some patients with angina pectoris, it is considerably less effective than nitroglycerin, both in the degree to which the exercise tolerance is increased and in the number of patients benefited.
One possible reason for this discrepancy might lie inl the different routes of administration used with these 2 drugs. Erythrol tetranitrate is a solid and hence, unlike nitroglycerin, is administered in tablets to be swallowed. In studying the comparative value of the different nitrites, therefore, it is necessary to compare the effect of oral, sublingual, and parenteral administration.
Maniiitol hexainitrate resembles glycerol trinitrate and erythrol tetranitrate in that it is prepared by nitration of a straight chain alcohol; in this instance the alcohol contains 6 carbon atoms and the nitrate contains 6 -ONO2 groups. Mannitol hexanitrate, like erythrol tetranitrate and the other compounds to be described, is a solid and is prescribed to be swallowed. Studies in this laboratory5' 21 indicated that mannitol hexanitrate when given in this manner is only of moderate benefit to patients with angina pectoris.
Pentaerythritol tetranitrate like erythrol tetranitrate, has 4 -ONO2 groups; the structural configuration and physical characteristics of pentaerythritol tetranitrate, however, are quite different from those of erythrol tetranitrate or nitroglycerin. 12'13 This drug has been the subject of a number of clinical investigations. The purely subjective methods of study22-28 uniformly indicated good results but this is true of most evaluations of therapy in angina pectoris, where purely subjective criteria are employed. Several objective studies showed improvement in the exercise electrocardiogram or clinical NITROGLYCERIN H2-C-0-NOt Sodium nitrite is the simplest nitrite available. Studies in laboratory animals45 indicated that it is a highly effective coronary vasodilator but it has proved ineffective when given in 60 mg. doses to patients with angina pectoris.' In laboratory studies the drug is given parenterally and in doses (considering the weight of the subjects) considerably larger than those given orally to human subjects.
METHODS
The methods of study have been described in detail elsewhere." 6 Oral or Swallowed Medication. Nitroglyn was given twice daily, all others 3 times daily (on arising, at 2:00 to 3:00 p.m., and on retiring) for 1 week and the Standardized Exercise Tolerance Test was performed from 1 to 2 hours after the last morning dose.
Nitroglycerin was given in 2 forms. In order to prevent absorption from the oral mucous membranes, hypodermic nitroglycerin tablets were encased in gelatin capsules before being swallowed. The minimum dose used in these studies was 0.45 mg. t.i.d. In order to determine the effective dose of nitroglycerin when swallowed, doses of 1 to 15 mg. (in capsules containing 1 mg. or 3 mg. each) were given to 13 patients. Studies with Nitroglyn were also carried out with varying doses.
Erythrol tetranitrate was administered in doses of 30 mg. 3 times daily for at least 1 week.
Mannitol hexanitrate was given in doses of 65 ng.
After preliminary studies with 2 mg. tablets, the dosage of triethanolamine trinitrate biphosphate used was 6 mg., 3 times daily for at least a week.
The dosage of pentaerythritol tetranitrate used was 40 to 50 mg. 3 times a day; several subjects also took 10 mg. 3 times a day.
Twenty-nine patients were requested to take 300 mg. of sodium nitrite 3 times daily for 1 week. Patients who developed untoward effects to this dose were given smaller doses.
Inunction. These studies were carried out with nitroglycerin and erythrol tetranitrate ointments.
Four inches of Nitrol Ointment (containing approximately 43 mg. of nitroglycerin) were rubbed in well twice daily for 1 week. The Standardized Exercise Tolerance Test was performed approximately 2 hours after the last dose.
The erythrol tetranitrate material for inunction was made by incorporating the specially prepared hypodermic tablets in a water soluble ointment base. An amount containing approximately 65 mg. of erythrol tetranitrate was rubbed in well, morning and night for 1 week and the exercise test carried out 2 hours after the last application.
Analysis of Results
The results were evaluated by studying the patient's record of the number of attacks experienced during each period of therapy; by asking the patient's opinion of the effectiveness of the treatment; and, most important, by measurement of the patient's exercise tolerance under the standardized conditions of the test. The following de 
RESULTS
The results are presented in tables 1 and 2. As in previous studies2-6' 47, 50, 52 the 20 group 1 subjects were far more likely to respond to other medication than were the 5 group 2 or the 9 group 3 patients. Comparison of the effects of medication, therefore, is best observed in group 1 subjects ( fig. 2) .
Nitroglycerin
Sublingual Administration. The dosage used caused no untoward effects in the 34 subjects. Thirteen of the 20 group 1 patients were able to exercise until fatigued without developing angina. The remaining 7 were able to increase their exercise tolerance by 62 to 135 per cent before they developed angina.
Subcutaneous Administration. In 7 of the 10 group 1 subjects, the degree of beneficial response was comparable to that following sublingual administration of the same dose.
Oral Administration. Thirteen of the 15 group 1 subjects who swallowed capsules containing 0.45 mg. of nitroglycerin showed no significant response while only 2 showed "moderate" increases in exercise tolerance. The swallowed dose of nitroglycerin necessary to increase the ability to exercise is shown in table 3. In 11 group 1 subjects, a "marked response" required a minimum of 2 or 3 mg. in 3 patients, 5 or 6 mg. in 2 patients, and 15 mg. in 2 patients. Two other patients showed a moderate response to 2 or 4 mg. but did not receive larger doses. The remaining 2 subjects failed to show a response after 15 mg. There were no untoward effects.
Fourteen group 1 subjects received Nitroglyn (table 3) . Six showed a "marked response;" 1, after 1 tablet (6 mg.) ; 2, following 12 mg.; 3 required 18, 24, and 30 mg., respectively. Two additional patients showed a "moderate response" after 12 and 24 mg., respectively. Two patients showed no response to as much as 30 mg. The remaining 4 showed no response after 12 mg., but received no larger doses.
Administration by Inunction (table 4) . One of 6 group 1 patients showed a "marked response " to Nitrol Ointment and 3 others showed responses that were "moderate" but appreciably less than followed sublingual nitroglycerin in the same patients. 
